

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vanguard CPV-L

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Quantity per 1 ml dose

#### **Active substances:**

Live attenuated canine Parvovirus, strain NL-35-D, low passage, minimum titre:  $10^{7.0}$  CCID<sub>50</sub>\*

Inactivated *Leptospira canicola*, between 420 and 740 RU\*\*/dose

Inactivated *Leptospira icterohaemorrhagiae*, between 463 to 915 RU\*\*/dose

\*Cell culture infectious dose-50

\*\* Relative units

For full list of excipients, see Section 6.1

### **3. PHARMACEUTICAL FORM**

Solution for injection

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Dogs

#### **4.2 Indications for use, specifying the target species**

Active immunisation of dogs to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c), and to reduce clinical signs and infection due to *Leptospira canicola* and *Leptospira icterohaemorrhagiae*.

Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Scheme. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.

The duration of immunity is at least 12 months.

#### **4.3 Contraindications**

Do not use in unhealthy animals.

#### **4.4 Special warnings for each target species**

The canine parvovirus vaccinal strains may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.

High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA are present (for example against the CPV component), this should be taken into account when planning the timing of vaccinations.

#### **4.5 Special precautions for use**

- i. Special precautions for use in animals

None

- ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.

#### **4.6 Adverse reactions (frequency and seriousness)**

Vaccinated dogs may have a transient swelling 4-6 hours after vaccination which resolves after approximately 7 days.

If a systemic anaphylactic reaction occurs (eg vomiting), administer adrenaline or an equivalent.

#### **4.7 Use during pregnancy, lactation or lay**

Do not use during pregnancy.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except when used with vaccines from the Vanguard range containing canine distemper virus, canine adenovirus or canine parainfluenza virus. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

##### Dosage and route of administration:

Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilised syringes or needles, as these will interfere with the effectiveness of the vaccine.

##### Basic Vaccination Scheme:

###### *Puppies younger than 10 weeks of age*

Two doses of Vanguard CPV-L at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age.

###### *Puppies 10 weeks of age and older*

A single dose of Vanguard CPV-L, followed by a single dose of Vanguard Lepto-ci at least 14 days later

##### Re-vaccination Scheme:

A single dose of Vanguard CPV-L to be given annually thereafter

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Occasional transient swellings may occur at the injection site after vaccination with an overdose.

No treatment is necessary in most cases of overdose. However, if a systemic anaphylactic reaction occurs (eg vomiting), administer adrenaline or an equivalent.

#### **4.11 Withdrawal period**

Not applicable.

### **5. IMMUNOLOGICAL PROPERTIES**

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parvovirus, *Leptospira canicola* and *Leptospira icterohaemorrhagiae*.

ATC vet code: QI07AI05

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Neomycin  
Gentamycin

### **6.2 Incompatibilities**

Do not mix with any other vaccine or immunological product.

### **6.3 Shelf life**

4 years.

### **6.4 Special precautions for storage**

Store and transport at +2°C to +8°C. Do not freeze.

### **6.5 Nature and composition of immediate packaging**

The vaccine is filled in 1 dose vials glass Type I (Ph Eur), closed with a chlorobutyl rubber stopper and a varnished aluminium cap.

Pack contains 1, 10, 25 or 100 vials of 1 ml Vanguard™ CPV-L.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

**8. MARKETING AUTHORISATION NUMBER**


Vm 42058/4159

**9. DATE OF FIRST AUTHORISATION**

28 October 2005

**10. DATE OF REVISION OF THE TEXT**

December 2023

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 06 December 2023